We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Concomitant Gastric Acid Suppressants on the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis.
- Authors
Xia, Jun; Zhu, Jiping; Li, Lei; Xu, Shiqin
- Abstract
<bold>Background: </bold>The influence of concomitant use of gastric acid suppressants (AS) on survival of patients with non-small-cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is inconsistent according to previous studies. We performed a meta-analysis to evaluate the effect of additional AS in patients with NSCLC taking TKIs.<bold>Methods: </bold>Relevant observational studies were identified by a search of Medline, Embase, and Web of Science databases. Only studies with multivariate analyses were included. A random-effect model was used to combine the results.<bold>Results: </bold>Thirteen retrospective studies with 12259 patients were included. Pooled results showed that concomitant use of AS was associated with worse progression-free survival (PFS, adjusted hazard ratio (HR): 1.57, 95% confidence interval (CI): 1.31 to 1.89, P < 0.001; I2 = 65%) and overall survival (OS, adjusted HR: 1.38, 95% CI: 1.19 to 1.61, P < 0.001; I2 = 70%) in NSCLC patients taking TKIs. Sensitivity analysis limited to studies including NSCLC with EGFR mutation showed consistent results (HR for PFS: 1.53, P=0.003; HR for OS: 1.43, P=0.001). Subgroup analyses indicated that the association between concomitant use of AS and poor survival was not significantly affected by the category of AS used (proton pump inhibitors or histamine type-2 receptor antagonists) or the country of the study (Asian or non-Asian, P for subgroup analysis all >0.05).<bold>Conclusions: </bold>Concomitant use of AS in patients with NSCLC taking TKIs may be associated with poor survival outcomes.
- Subjects
LUNG cancer; META-analysis; PROTEIN kinase inhibitors; LUNG tumors; RETROSPECTIVE studies; CELL receptors; GASTRIC acid
- Publication
International Journal of Clinical Practice, 2022, p1
- ISSN
1368-5031
- Publication type
journal article
- DOI
10.1155/2022/3102641